Iridex Corporation reported third quarter 2025 revenue of $12.5 million, an 8.0% increase from $11.6 million in the same period of 2024. Revenue from the Cyclo G6 product family reached $3.5 million, up 13.0% year-over-year from $3.1 million. The company sold 14,900 Cyclo G6 probes compared to 13,600 a year earlier, and 30 Cyclo G6 Glaucoma Laser Systems versus 26 in the prior year quarter. Other revenue increased by $0.2 million to $2.2 million, mainly due to higher service revenue and sales of legacy products, partially offset by decreased royalties following patent expirations. As of September 27, 2025, cash and cash equivalents were $5.6 million, down $1.2 million for the quarter. Iridex expects to achieve positive adjusted EBITDA for the full year 2025 and anticipates cash flow breakeven in the fourth quarter.